Opinion|Videos|February 7, 2025
An Overview to Myelofibrosis and Disease Risk
Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What outstanding updates in PV from ASH 2024 are noteworthy?
- What do you see for the future of PV treatment?
- What are the greatest unmet needs?
- How are ongoing investigational therapies helping to address these unmet needs?
- What clinical pearls can you share for community oncologists?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5